A Phase 2 interventional study of ODM-201 in Prostate Cancer, sponsored by Orion Corporation, Orion Pharma. Completed at 17 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-20.
Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 32nd largest by enrollment, is one of 2 that started in 2011, is one of 29 in phase 2, and was the 2nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
Region Stockholm · Sites in Sweden
Ages 18+ · Men only
By country, each count listing its studies:
darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 34 · Phase 3 14 · Phase 4 4
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 80 across the 59 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 6 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies testing darolutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT06173362University of California, DavisAbiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | 2026-11 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT05762536Erasmus Medical CenterDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 59 studies testing darolutamide in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ODM-201
ODM-201 administered orally daily
Number of Participants With Adverse Events
Adverse events from start of ODM-201 treatment (in ARADES 3104001 study) until end of study visit (in ARADES-EXT 3104002 study). Median duration on study treatment was 11,0 months.
Time frame: From first dose of study treatment up to 4 weeks after last dose of study treatment
Participants were enrolled at 17 hospitals in Europe and in the USA
| Milestone | Patients From Arades 3104001 Dose Escalation | Patients From Arades 3104001 Dose Expansion (200mg/Day) | Patients From Arades 3104001 Dose Expansion (400mg/Day) | Patients From Arades 3104001 Dose Expansion (1400mg/Day) |
|---|---|---|---|---|
| Started | 19 | 22 | 19 | 16 |
| Completed | 19 | 22 | 19 | 16 |
| Not completed | 0 | 0 | 0 | 0 |
Adverse events from start of ODM-201 treatment (in ARADES 3104001 study) until end of study visit (in ARADES-EXT 3104002 study). Median duration on study treatment was 11,0 months.
| participants | Patients From Arades 3104001 Dose Escalation | Patients From Arades 3104001 Dose Expansion (200mg/Day) | Patients From Arades 3104001 Dose Expansion (400mg/Day) | Patients From Arades 3104001 Dose Expansion (1400mg/Day) |
|---|---|---|---|---|
| Number of Participants With Adverse Events | 19 | 22 | 19 | 16 |
Collected over From first dose of study treatment up to 4 weeks after last dose of study treatment. Median duration on study treatment was 11,0 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients From Arades 3104001 Dose Escalation | — | 5/19 (26.3%) | 19/19 (100%) |
| Patients From Arades 3104001 Dose Expansion (200mg/Day) | — | 7/22 (31.8%) | 22/22 (100%) |
| Patients From Arades 3104001 Dose Expansion (400mg/Day) | — | 3/19 (15.8%) | 19/19 (100%) |
| Patients From Arades 3104001 Dose Expansion (1400mg/Day) | — | 4/16 (25%) | 16/16 (100%) |
| Event | Patients From Arades 3104001 Dose Escalation | Patients From Arades 3104001 Dose Expansion (200mg/Day) | Patients From Arades 3104001 Dose Expansion (400mg/Day) | Patients From Arades 3104001 Dose Expansion (1400mg/Day) |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/19 | 0/22 | 1/19 | 2/16 |
| Acute kidney injuryRenal and urinary disorders | 0/19 | 2/22 | 0/19 | 0/16 |
| NauseaGastrointestinal disorders | 0/19 | 0/22 | 0/19 | 1/16 |
| ChillsGeneral disorders | 0/19 | 0/22 | 0/19 | 1/16 |
| PyrexiaGeneral disorders | 0/19 | 1/22 | 0/19 | 1/16 |
| PneumoniaInfections and infestations | 0/19 | 0/22 | 0/19 | 1/16 |
| UrosepsisInfections and infestations | 0/19 | 1/22 | 0/19 | 1/16 |
| Enterobacter test positiveInvestigations | 0/19 | 0/22 | 0/19 | 1/16 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/19 | 0/22 | 0/19 | 1/16 |
| Urinary incontinenceRenal and urinary disorders | 0/19 | 0/22 | 0/19 | 1/16 |
| Event | Patients From Arades 3104001 Dose Escalation | Patients From Arades 3104001 Dose Expansion (200mg/Day) | Patients From Arades 3104001 Dose Expansion (400mg/Day) | Patients From Arades 3104001 Dose Expansion (1400mg/Day) |
|---|---|---|---|---|
| FatigueGeneral disorders | 5/19 | 3/22 | 5/19 | 8/16 |
| DiarrhoeaGastrointestinal disorders | 9/19 | 0/22 | 2/19 | 1/16 |
| Back painMusculoskeletal and connective tissue disorders | 7/19 | 4/22 | 5/19 | 6/16 |
| PainGeneral disorders | 4/19 | 7/22 | 1/19 | 3/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/19 | 7/22 | 3/19 | 3/16 |
| Oedema peripheralGeneral disorders | 3/19 | 2/22 | 1/19 | 5/16 |
| NauseaGastrointestinal disorders | 5/19 | 2/22 | 3/19 | 3/16 |
| AstheniaGeneral disorders | 5/19 | 1/22 | 2/19 | 0/16 |
| Decreased appetiteMetabolism and nutrition disorders | 1/19 | 3/22 | 5/19 | 2/16 |
| NasopharyngitisInfections and infestations | 4/19 | 2/22 | 1/19 | 1/16 |
Safety
| Age, Continuous(years) | Patients From Arades 3104001 Dose Escalation | Patients From Arades 3104001 Dose Expansion (200mg/Day) | Patients From Arades 3104001 Dose Expansion (400mg/Day) | Patients From Arades 3104001 Dose Expansion (1400mg/Day) | Total |
|---|---|---|---|---|---|
| Mean | 68.8 ± 6.1 | 66.5 ± 6.6 | 68.9 ± 8.3 | 74.6 ± 6.3 | 69.4 ± 7.3 |
| Gender(Participants) | Patients From Arades 3104001 Dose Escalation | Patients From Arades 3104001 Dose Expansion (200mg/Day) | Patients From Arades 3104001 Dose Expansion (400mg/Day) | Patients From Arades 3104001 Dose Expansion (1400mg/Day) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 19 | 22 | 19 | 16 | 76 |
The record gives a start of Jun 2011, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darolutamide
Orion Corporation, Orion Pharma →